{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=6", "query": { "intervention": "T cells", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 3573, "total_pages": 358, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T17:22:38.200Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00031941", "title": "CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-04", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031941" }, { "nct_id": "NCT06904066", "title": "Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignancy, Hematologic", "Neoplasms, Hematologic", "Neoplasms, Hematopoietic", "Blood Cancer", "Hematological Neoplasms", "Hematopoietic Malignancies", "Dysmyelopoietic Syndromes", "Hematopoetic Myelodysplasia", "Myeloid Leukemia, Acute", "Nonlymphoblastic Leukemia, Acute", "Leukemia, Lymphocytic, Acute" ], "interventions": [ { "name": "aldesleukin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "TruSight Oncology (TSO) 500", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 86, "start_date": "2026-10-28", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06904066" }, { "nct_id": "NCT01078337", "title": "T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia, Lymphocytic, Acute" ], "interventions": [ { "name": "bone marrow aspiration", "type": "PROCEDURE" }, { "name": "peripheral blood sampling", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 15, "start_date": "2002-11", "completion_date": "2007-10", "has_results": false, "last_update_posted_date": "2010-03-02", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01078337" }, { "nct_id": "NCT05107674", "title": "A Study of NX-1607 in Adults With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "NX-1607", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2021-09-29", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107674" }, { "nct_id": "NCT02917096", "title": "Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Myelofibrosis", "Secondary Myelofibrosis" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2016-11-13", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02917096" }, { "nct_id": "NCT04934670", "title": "A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Steroid-Refractory Acute Graft Versus Host Disease" ], "interventions": [ { "name": "T-Guard", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xenikos", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-06-16", "completion_date": "2023-01-19", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • Tampa, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04934670" }, { "nct_id": "NCT07586618", "title": "First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Lymphoma", "Acute Lymphoblastic Leukemia ALL" ], "interventions": [ { "name": "4A10", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allterum Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-06-01", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 7, "location_summary": "Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07586618" }, { "nct_id": "NCT00935090", "title": "3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "3'-deoxy-3'-[18F]fluorothymidine", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2009-09", "completion_date": "2027-04-04", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00935090" }, { "nct_id": "NCT00061880", "title": "BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "forodesine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioCryst Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-02", "completion_date": "2008-01", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061880" }, { "nct_id": "NCT01943188", "title": "Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Recurrent Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "stereotactic body radiation therapy", "type": "RADIATION" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-11-12T17:22:38.200Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01943188" } ] }